Please ensure Javascript is enabled for purposes of website accessibility

FDA Authorizes Becton, Dickinson Portable 15-Minute Coronavirus Test

By Eric Volkman – Updated Jul 8, 2020 at 11:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The test is based on the company's BD Veritor Plus System, a handheld diagnostic device.

A new test for the SARS-CoV-2 coronavirus and the COVID-19 disease that results from it is now available on the market. Healthcare technology specialist Becton, Dickinson (BDX -1.76%) announced Monday that it has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for an antigen test that can effectively detect the presence of the coronavirus.

The test is used in combination with the company's BD Veritor Plus System, a handheld electronic diagnostic machine. The small profile of this device makes it very portable, and thus ideal for situations where testing must occur at the many point-of-care locations now scattered throughout the country.

According to Becton, Dickinson, it is also very fast; the company says it can produce results in 15 minutes.

Becton Dickinson rapid coronavirus testing kit.

Image source: Becton Dickinson.

At the moment, according to Becton, Dickinson, the BD Veritor Plus System is in use in over 25,000 healthcare facilities within the U.S. It is used to test for illnesses such as flu.

"This will be a game-changer for frontline healthcare workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers and doctors' offices," Becton, Dickinson said in the press release trumpeting the FDA's authorization.

The company said that it can quickly ramp up production to make 2 million coronavirus tests per week by the end of September. Prior to that, it believes it can pump out 10 million tests between now and that time.

Investors greeted the news by pushing Becton, Dickinson's share price up by 2.2% on Monday. That slightly outpaced the gains recorded by the major stock indexes on the day.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
$227.57 (-1.76%) $-4.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.